<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860262</url>
  </required_header>
  <id_info>
    <org_study_id>1235.20</org_study_id>
    <secondary_id>2008-000873-40</secondary_id>
    <nct_id>NCT00860262</nct_id>
  </id_info>
  <brief_title>Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension</brief_title>
  <official_title>An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg &amp; Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to demonstrate that following eight weeks of treatment
      the FDC of telmisartan 80 mg plus amlodipine 10 mg (T80/A10) is superior as first line
      therapy in reducing mean seated trough cuff Systolic Blood Pressure [SBP] compared to the
      monotherapies of telmisartan 80 mg (T80) and amlodipine 10 mg (A10) in patients with severe
      hypertension. A key secondary objective is to identify the duration of treatment required to
      demonstrate the superiority of the FDC over both of the monotherapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>Overall mean reduction from a common mean baseline in SBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6</measure>
    <time_frame>baseline and week 6</time_frame>
    <description>Overall mean reduction from a common mean baseline in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4</measure>
    <time_frame>baseline and week 4</time_frame>
    <description>Overall mean reduction from a common mean baseline in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2</measure>
    <time_frame>baseline and week 2</time_frame>
    <description>Overall mean reduction from a common mean baseline in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1</measure>
    <time_frame>baseline and week 1</time_frame>
    <description>Overall mean reduction from a common mean baseline in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>Overall mean reduction from a common mean baseline in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6</measure>
    <time_frame>baseline and week 6</time_frame>
    <description>Overall mean reduction from a common mean baseline in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4</measure>
    <time_frame>baseline and week 4</time_frame>
    <description>Overall mean reduction from a common mean baseline in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2</measure>
    <time_frame>baseline and week 2</time_frame>
    <description>Overall mean reduction from a common mean baseline in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1</measure>
    <time_frame>baseline and week 1</time_frame>
    <description>Overall mean reduction from a common mean baseline in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Control at Week 1</measure>
    <time_frame>week 1</time_frame>
    <description>Diastolic Blood Pressure Control is defined as achieving DBP &lt; 90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Control at Week 2</measure>
    <time_frame>week 2</time_frame>
    <description>DBP &lt; 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Blood Pressure Control at Week 1</measure>
    <time_frame>week 1</time_frame>
    <description>Blood Pressure Control is defined as achieving SBP&lt; 140 mmHg and DBP &lt; 90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Blood Pressure Control at Week 2</measure>
    <time_frame>week 2</time_frame>
    <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Response at Week 1</measure>
    <time_frame>baseline, week 1</time_frame>
    <description>Diastolic Blood Pressure Response is defined as achieving DBP &lt; 90 mmHg or a reduction of &gt;= 10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Response at Week 2</measure>
    <time_frame>baseline, week 2</time_frame>
    <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Systolic Blood Pressure Response at Week 1</measure>
    <time_frame>baseline, week 1</time_frame>
    <description>Systolic Blood Pressure Response Control is defined as achieving SBP &lt; 140 mmHg or a reduction of &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Systolic Blood Pressure Response at Week 2</measure>
    <time_frame>baseline, week 2</time_frame>
    <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Various Blood Pressure Response Levels at Week 1</measure>
    <time_frame>week 1</time_frame>
    <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Various Blood Pressure Response Levels at Week 2</measure>
    <time_frame>week 2</time_frame>
    <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Control at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>DBP &lt; 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Control at Week 6</measure>
    <time_frame>week 6</time_frame>
    <description>DBP &lt; 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Control at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>DBP &lt; 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Blood Pressure Control at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Blood Pressure Control at Week 6</measure>
    <time_frame>week 6</time_frame>
    <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Blood Pressure Control at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Response at Week 4</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Response at Week 6</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Diastolic Blood Pressure Response at Week 8</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Systolic Blood Pressure Response at Week 4</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Systolic Blood Pressure Response at Week 6</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Systolic Blood Pressure Response at Week 8</measure>
    <time_frame>baseline, week 8</time_frame>
    <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Normal Blood Pressure Response at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Normal Blood Pressure Response at Week 6</measure>
    <time_frame>week 6</time_frame>
    <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Normal Blood Pressure Response at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">858</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>telmisartan and amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telmisartan and amlodipine used in combination vs amlodipine or telmisartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>telmisartan and amlodipine used in combination vs amlodipine or telmisartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>telmisartan and amlodipine used in combination vs amlodipine or telmisartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
    <description>amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w</description>
    <arm_group_label>amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan</intervention_name>
    <description>telmisartan 80mg for the 8w, no titration required</description>
    <arm_group_label>telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan and amlodipine</intervention_name>
    <description>telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w</description>
    <arm_group_label>telmisartan and amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Ability to provide written informed consent in accordance with Good Clinical Practice
             and local legislation

          2. Age 18 years or older

          3. Patients with severe hypertension as defined SBP greater than 180 mmHg and DBP greater
             than 95 mmHg at randomisation

          4. Ability to stop any current antihypertensive therapy without unacceptable risk to the
             patient (Investigators discretion)

        Exclusion criteria Mean in-clinic seated cuff SBP &gt;/= 200 mmHg and/or Diastolic Blood
        Pressure [DBP] &gt;/= 95 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.20.525 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.507 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.529 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.518 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.521 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.508 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.519 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.523 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.528 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.516 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.527 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.510 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.512 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.509 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.511 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.515 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.534 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.526 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.513 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.517 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.522 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.520 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.530 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.535 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.533 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Magna</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratoga Springs</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.537 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Benatky nad Jizerou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cesky Krumlov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pribram</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strakonice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.101A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.102F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.103A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beziers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.103C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beziers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.103F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beziers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.106A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourg des cptes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.109B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brive</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.108E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carbonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.101D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.103E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cournonterral</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.108C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cugnaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.106D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Etrelles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.108F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fenouillet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.102A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gemenos</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.102C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gemenos</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.101C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gresy Sur Aix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.108A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Labarthe Sur Leze</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.108B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Labarthe sur Leze</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.106F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louvigne De bais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.102E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.106B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mordelles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.107A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ortez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.107B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orthez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.107E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orthez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.107G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orthez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.109A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosiers d'Egletons</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.109F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Aulaire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.104A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.104D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.107F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salies de Bearn</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.105A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.105D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.152 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.156 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.158 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.159 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.161 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyongyos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.157 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.155 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chunan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.252 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.259 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.262 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.254 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.261 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.256 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.251 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.260 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tg. Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.253 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.310 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.309 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.311 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.355 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Galanta</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.353 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.352 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.354 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.356 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.351 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vrable</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.451 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.458 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.460 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.453 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.454 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.455 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.456 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.457 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.461 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.452 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.20.459 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <results_first_submitted>December 10, 2010</results_first_submitted>
  <results_first_submitted_qc>December 10, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2011</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T80+A10</title>
          <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
        </group>
        <group group_id="P2">
          <title>Telmisartan 80 mg</title>
          <description>Telmisartan 80 mg once daily (T80)</description>
        </group>
        <group group_id="P3">
          <title>Amlodipine 10 mg</title>
          <description>Amlodipine 10 mg once daily (A10)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="421"/>
                <participants group_id="P2" count="217"/>
                <participants group_id="P3" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="401"/>
                <participants group_id="P2" count="195"/>
                <participants group_id="P3" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T80+A10</title>
          <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
        </group>
        <group group_id="B2">
          <title>Telmisartan 80 mg</title>
          <description>Telmisartan 80 mg once daily (T80)</description>
        </group>
        <group group_id="B3">
          <title>Amlodipine 10 mg</title>
          <description>Amlodipine 10 mg once daily (A10)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="421"/>
            <count group_id="B2" value="217"/>
            <count group_id="B3" value="220"/>
            <count group_id="B4" value="858"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="10.4"/>
                    <measurement group_id="B2" value="58.1" spread="10.2"/>
                    <measurement group_id="B3" value="58.6" spread="10.5"/>
                    <measurement group_id="B4" value="58.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilograms/square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="5.9"/>
                    <measurement group_id="B2" value="30.2" spread="5.2"/>
                    <measurement group_id="B3" value="30.7" spread="6.3"/>
                    <measurement group_id="B4" value="30.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index Class</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>BMI &lt; 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 &lt;= BMI &lt; 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMI &gt;= 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race Class</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="387"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="205"/>
                    <measurement group_id="B4" value="794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type II Diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Hypertension</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.3" spread="9.6"/>
                    <measurement group_id="B2" value="9.4" spread="9.2"/>
                    <measurement group_id="B3" value="10.3" spread="10.1"/>
                    <measurement group_id="B4" value="10.1" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Hypertension Class</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 - 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of previous antihypertensive treatments</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8</title>
        <description>Overall mean reduction from a common mean baseline in SBP</description>
        <time_frame>baseline and week 8</time_frame>
        <population>Full analysis set (FAS) included all randomised patients who had at least one seated trough cuff SBP following administration of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8</title>
          <description>Overall mean reduction from a common mean baseline in SBP</description>
          <population>Full analysis set (FAS) included all randomised patients who had at least one seated trough cuff SBP following administration of study drug.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.5" spread="0.69"/>
                    <measurement group_id="O2" value="-36.9" spread="0.96"/>
                    <measurement group_id="O3" value="-43.2" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.9</ci_lower_limit>
            <ci_upper_limit>-8.3</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus Telmisartan 80 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>-2.1</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus amlodipine 10 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6</title>
        <description>Overall mean reduction from a common mean baseline in SBP</description>
        <time_frame>baseline and week 6</time_frame>
        <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6</title>
          <description>Overall mean reduction from a common mean baseline in SBP</description>
          <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.9" spread="0.73"/>
                    <measurement group_id="O2" value="-36.3" spread="1.01"/>
                    <measurement group_id="O3" value="-42.1" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.1</ci_lower_limit>
            <ci_upper_limit>-8.2</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus telmisartan 80 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus amlodipine 10 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4</title>
        <description>Overall mean reduction from a common mean baseline in SBP</description>
        <time_frame>baseline and week 4</time_frame>
        <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4</title>
          <description>Overall mean reduction from a common mean baseline in SBP</description>
          <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.5" spread="0.73"/>
                    <measurement group_id="O2" value="-34.4" spread="1.01"/>
                    <measurement group_id="O3" value="-39.8" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.6</ci_lower_limit>
            <ci_upper_limit>-7.7</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus telmisartan 80 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus amlodipine 10 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2</title>
        <description>Overall mean reduction from a common mean baseline in SBP</description>
        <time_frame>baseline and week 2</time_frame>
        <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2</title>
          <description>Overall mean reduction from a common mean baseline in SBP</description>
          <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.9" spread="0.71"/>
                    <measurement group_id="O2" value="-30.1" spread="0.97"/>
                    <measurement group_id="O3" value="-33.3" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>-5.4</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus telmisartan 80 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>-2.3</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus amlodipine 10 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1</title>
        <description>Overall mean reduction from a common mean baseline in SBP</description>
        <time_frame>baseline and week 1</time_frame>
        <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1</title>
          <description>Overall mean reduction from a common mean baseline in SBP</description>
          <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.9" spread="0.72"/>
                    <measurement group_id="O2" value="-25.4" spread="0.99"/>
                    <measurement group_id="O3" value="-28.6" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>-4.0</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus telmisartan 80 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>Repeated measures ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
            <estimate_desc>Difference calculated as T80+A10 minus amlodipine 10 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8</title>
        <description>Overall mean reduction from a common mean baseline in DBP</description>
        <time_frame>baseline and week 8</time_frame>
        <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8</title>
          <description>Overall mean reduction from a common mean baseline in DBP</description>
          <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" spread="0.41"/>
                    <measurement group_id="O2" value="-13.8" spread="0.58"/>
                    <measurement group_id="O3" value="-16.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6</title>
        <description>Overall mean reduction from a common mean baseline in DBP</description>
        <time_frame>baseline and week 6</time_frame>
        <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6</title>
          <description>Overall mean reduction from a common mean baseline in DBP</description>
          <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="0.41"/>
                    <measurement group_id="O2" value="-13.5" spread="0.57"/>
                    <measurement group_id="O3" value="-15.7" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4</title>
        <description>Overall mean reduction from a common mean baseline in DBP</description>
        <time_frame>baseline and week 4</time_frame>
        <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4</title>
          <description>Overall mean reduction from a common mean baseline in DBP</description>
          <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" spread="0.43"/>
                    <measurement group_id="O2" value="-12.1" spread="0.60"/>
                    <measurement group_id="O3" value="-14.2" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2</title>
        <description>Overall mean reduction from a common mean baseline in DBP</description>
        <time_frame>baseline and week 2</time_frame>
        <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2</title>
          <description>Overall mean reduction from a common mean baseline in DBP</description>
          <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.2" spread="0.40"/>
                    <measurement group_id="O2" value="-10.4" spread="0.56"/>
                    <measurement group_id="O3" value="-11.4" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1</title>
        <description>Overall mean reduction from a common mean baseline in DBP</description>
        <time_frame>baseline and week 1</time_frame>
        <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1</title>
          <description>Overall mean reduction from a common mean baseline in DBP</description>
          <population>Full analysis set (FAS) included all patients who had efficacy data consisting of a baseline and at least one post-baseline trough BP measurement.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="0.37"/>
                    <measurement group_id="O2" value="-8.2" spread="0.50"/>
                    <measurement group_id="O3" value="-9.6" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Control at Week 1</title>
        <description>Diastolic Blood Pressure Control is defined as achieving DBP &lt; 90mmHg</description>
        <time_frame>week 1</time_frame>
        <population>Full analysis set, imputation method used was last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Control at Week 1</title>
          <description>Diastolic Blood Pressure Control is defined as achieving DBP &lt; 90mmHg</description>
          <population>Full analysis set, imputation method used was last observation carried forward (LOCF).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Control at Week 2</title>
        <description>DBP &lt; 90 mmHg</description>
        <time_frame>week 2</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Control at Week 2</title>
          <description>DBP &lt; 90 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Blood Pressure Control at Week 1</title>
        <description>Blood Pressure Control is defined as achieving SBP&lt; 140 mmHg and DBP &lt; 90mmHg</description>
        <time_frame>week 1</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Blood Pressure Control at Week 1</title>
          <description>Blood Pressure Control is defined as achieving SBP&lt; 140 mmHg and DBP &lt; 90mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="191"/>
                    <measurement group_id="O3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Blood Pressure Control at Week 2</title>
        <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
        <time_frame>week 2</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Blood Pressure Control at Week 2</title>
          <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                    <measurement group_id="O2" value="182"/>
                    <measurement group_id="O3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Response at Week 1</title>
        <description>Diastolic Blood Pressure Response is defined as achieving DBP &lt; 90 mmHg or a reduction of &gt;= 10 mmHg</description>
        <time_frame>baseline, week 1</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Response at Week 1</title>
          <description>Diastolic Blood Pressure Response is defined as achieving DBP &lt; 90 mmHg or a reduction of &gt;= 10 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Response at Week 2</title>
        <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
        <time_frame>baseline, week 2</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Response at Week 2</title>
          <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                    <measurement group_id="O2" value="123"/>
                    <measurement group_id="O3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Systolic Blood Pressure Response at Week 1</title>
        <description>Systolic Blood Pressure Response Control is defined as achieving SBP &lt; 140 mmHg or a reduction of &gt;= 15 mmHg</description>
        <time_frame>baseline, week 1</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Systolic Blood Pressure Response at Week 1</title>
          <description>Systolic Blood Pressure Response Control is defined as achieving SBP &lt; 140 mmHg or a reduction of &gt;= 15 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="164"/>
                    <measurement group_id="O3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Systolic Blood Pressure Response at Week 2</title>
        <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
        <time_frame>baseline, week 2</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Systolic Blood Pressure Response at Week 2</title>
          <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Various Blood Pressure Response Levels at Week 1</title>
        <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
        <time_frame>week 1</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Various Blood Pressure Response Levels at Week 1</title>
          <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="191"/>
                    <measurement group_id="O3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Various Blood Pressure Response Levels at Week 2</title>
        <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
        <time_frame>week 2</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A5</title>
            <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily (T80+A5)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg once daily (A5)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Various Blood Pressure Response Levels at Week 2</title>
          <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                    <measurement group_id="O2" value="182"/>
                    <measurement group_id="O3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Control at Week 4</title>
        <description>DBP &lt; 90 mmHg</description>
        <time_frame>week 4</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Control at Week 4</title>
          <description>DBP &lt; 90 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Control at Week 6</title>
        <description>DBP &lt; 90 mmHg</description>
        <time_frame>week 6</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Control at Week 6</title>
          <description>DBP &lt; 90 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Control at Week 8</title>
        <description>DBP &lt; 90 mmHg</description>
        <time_frame>week 8</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Control at Week 8</title>
          <description>DBP &lt; 90 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Blood Pressure Control at Week 4</title>
        <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
        <time_frame>week 4</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Blood Pressure Control at Week 4</title>
          <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Blood Pressure Control at Week 6</title>
        <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
        <time_frame>week 6</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Blood Pressure Control at Week 6</title>
          <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Blood Pressure Control at Week 8</title>
        <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
        <time_frame>week 8</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Blood Pressure Control at Week 8</title>
          <description>SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="161"/>
                    <measurement group_id="O3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Response at Week 4</title>
        <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
        <time_frame>baseline, week 4</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Response at Week 4</title>
          <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Response at Week 6</title>
        <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
        <time_frame>baseline, week 6</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Response at Week 6</title>
          <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Diastolic Blood Pressure Response at Week 8</title>
        <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
        <time_frame>baseline, week 8</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Diastolic Blood Pressure Response at Week 8</title>
          <description>DBP &lt; 90 mmHg or reduction of &gt;= 10 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Systolic Blood Pressure Response at Week 4</title>
        <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
        <time_frame>baseline, week 4</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Systolic Blood Pressure Response at Week 4</title>
          <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Systolic Blood Pressure Response at Week 6</title>
        <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
        <time_frame>baseline, week 6</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Systolic Blood Pressure Response at Week 6</title>
          <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388"/>
                    <measurement group_id="O2" value="184"/>
                    <measurement group_id="O3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Systolic Blood Pressure Response at Week 8</title>
        <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
        <time_frame>baseline, week 8</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Systolic Blood Pressure Response at Week 8</title>
          <description>SBP &lt; 140 mmHg or reduction of &gt;= 15 mmHg</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Controlled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Normal Blood Pressure Response at Week 4</title>
        <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
        <time_frame>week 4</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Normal Blood Pressure Response at Week 4</title>
          <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Normal Blood Pressure Response at Week 6</title>
        <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
        <time_frame>week 6</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Normal Blood Pressure Response at Week 6</title>
          <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Normal Blood Pressure Response at Week 8</title>
        <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
        <time_frame>week 8</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80+A10</title>
            <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg</title>
            <description>Telmisartan 80 mg once daily (T80)</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Amlodipine 10 mg once daily (A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Normal Blood Pressure Response at Week 8</title>
          <description>Optimal: SBP&lt;120 and DBP&lt; 80; Normal: 120&lt;=SBP&lt;130 and 80&lt;= DBP&lt;85; High normal: 130&lt;=SBP&lt;140 and 85&lt;=DBP&lt;90; High: SBP&gt;=140 or DBP&gt;=90</description>
          <population>FAS (LOCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="161"/>
                    <measurement group_id="O3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First study medication intake, last study medication intake + 6 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T80+A10</title>
          <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)</description>
        </group>
        <group group_id="E2">
          <title>Telmisartan 80 mg</title>
          <description>Telmisartan 80 mg once daily (T80)</description>
        </group>
        <group group_id="E3">
          <title>Amlodipine 10 mg</title>
          <description>Amlodipine 10 mg once daily (A10)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peridiverticular abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

